Efficacy And Safety Analysis Of Alirocumab In T2DM

Synopsis Diabetes mellitus is known to be associated with increased LDL-C levels. Alirocumab, a monoclonal antibody significantly reduces low-density lipoprotein cholesterol (LDL-C). The aims to evaluate the efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus (T2DM) with versus without mixed dyslipidemia. This week’s “MED FACT” discusses a clinical study from Atherosclerosis, “Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidemia: Analysis of the ODYSSEY LONG TERM trial” .

Authors:   Marja-Riitta Taskinen, Stefano Del Prato, Maja Bujas-Bobano et al. Key Takeaways: Alirocumab reduces low-density lipoprotein cholesterol (LDL-C) in individuals with T2DM with or without mixed dyslipidemia. Objective: To evaluate the efficacy and safety of alirocumab in individuals with T2DM with or without mixed…